Connecticut will get $756,280 as its share of a multi-state, multimillion-dollar settlement with drug giant GlaxoSmithKline and a Puerto Rican affiliate, the attorney general says.
George Jepsen announced Connecticut’s participation with 37 other states in a $40.75 million settlement with pharmaceutical companies GlaxoSmithKline LLC of Philadelphia and SB Pharmco Puerto Rico, Inc., an indirect subsidiary of GlaxoSmithKline plc, over alleged substandard manufacturing processes.
The attorneys general alleged the companies engaged in unfair and deceptive practices when they manufactured and distributed certain lots of four drugs because substandard manufacturing processes were used to produce these lots between 2001 and 2004.
The drugs affected were: Kytril, a sterile drug used to prevent nausea and vomiting caused by cancer chemotherapy and radiation therapy; Bactroban, an antibiotic ointment used to treat skin infections; Paxil CR, the controlled release formulation of the antidepressant drug Paxil; and Avandamet, a combination Type II diabetes drug.
The adulterated drugs were produced at the companies’ production facility in Cidra, Puerto Rico, which has been closed since 2009.
Connecticut’s share of the settlement is $756,280.
